Structurally Altered Peptides Reveal an Important Role for N-terminal Heptad Repeat Binding and Stability in the Inhibitory Action of HIV-1 Peptide DP178*

Human immunodeficiency virus 1 gp41 folds into a six-helix bundle whereby three C-terminal heptad repeat regions pack in an anti-parallel manner against the coiled-coil formed by three N-terminal heptad repeats (NHR). Peptides that inhibit bundle formation contributed significantly to the understanding of the entry mechanism of the virus. DP178, which partially overlaps C-terminal heptad repeats, prevents bundle formation through an undefined mechanism; additionally it has been suggested to bind other ENV regions and arrest fusion in an unknown manner. We used two structurally altered DP178 peptides; in each, two sequential amino acids were substituted into their d configuration, d-SQ in the hydrophilic N-terminal region and d-LW in the hydrophobic C-terminal. Importantly, we generated an elongated NHR peptide, N54, obtaining the full N-helix docking site for DP178. Interestingly, d-LW retained wild type fusion inhibitory activity, whereas d-SQ exhibited significantly reduced activity. In correlation with the inhibitory data, CD spectroscopy and fluorescence studies revealed that all the DP178 peptides interact with N54, albeit with different stabilities of the bundles. We conclude that strong binding of DP178 N-terminal region to the endogenous NHR, without significant contribution of the C-terminal sequence of DP178 to core formation, is vital for DP178 inhibition. The finding that d-amino acid incorporation in the C terminus did not affect activity or membrane binding as revealed by surface plasmon resonance correlates with an additional membrane binding site, or membrane anchoring role, for the C terminus, which works synergistically with the N terminus to inhibit fusion.

[1]  G. Melikyan,et al.  Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion , 2000, The Journal of cell biology.

[2]  R. B. Merrifield,et al.  Synthesis of the antibacterial peptide cecropin A (1-33). , 1982, Biochemistry.

[3]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[4]  Y. Shai,et al.  Interaction of D-amino acid incorporated analogues of pardaxin with membranes. , 1992, Biochemistry.

[5]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[6]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[7]  Min Lu,et al.  Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion. , 2002, Biochemistry.

[8]  Y. Shai,et al.  Hetero-assembly between all-L- and all-D-amino acid transmembrane domains: forces involved and implication for inactivation of membrane proteins. , 2004, Journal of molecular biology.

[9]  Y. Shai,et al.  Mode of action of the antibacterial cecropin B2: a spectrofluorometric study. , 1994, Biochemistry.

[10]  S. Durell,et al.  Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.

[11]  S. Hammer,et al.  HIV fusion and its inhibition. , 2001, Antiviral research.

[12]  Y. Shai,et al.  Structural adaptation of the glycophorin A transmembrane homodimer to D-amino acid modifications. , 2004, Journal of molecular biology.

[13]  Y. G. Yu,et al.  Two interaction modes of the gp41-derived peptides with gp41 and their correlation with antimembrane fusion activity. , 1999, Biochemical and biophysical research communications.

[14]  Y. Shai,et al.  Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. , 2000, Journal of molecular biology.

[15]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[16]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[17]  S. A. Gallo,et al.  Mode of Action of an Antiviral Peptide from HIV-1 , 2001, The Journal of Biological Chemistry.

[18]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[19]  I. Chaiken,et al.  Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integrated rate equation, and numerical integration. , 1995, Analytical biochemistry.

[20]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[21]  Y. Shai,et al.  Channel formation properties of synthetic pardaxin and analogues. , 1990, The Journal of biological chemistry.

[22]  J. Werkmeister,et al.  Analysis of antimicrobial peptide interactions with hybrid bilayer membrane systems using surface plasmon resonance. , 2001, Biochimica et biophysica acta.

[23]  Y. Hayek,et al.  A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. , 2002, Biochemistry.

[24]  S. A. Gallo,et al.  The HIV Env-mediated fusion reaction. , 2003, Biochimica et biophysica acta.

[25]  G. Pavlakis,et al.  A bioassay for HIV-1 based on Env-CD4 interaction. , 1990, AIDS research and human retroviruses.

[26]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Harrison,et al.  Structural basis for membrane fusion by enveloped viruses. , 1999, Molecular membrane biology.

[28]  Niv Papo,et al.  Exploring peptide membrane interaction using surface plasmon resonance: differentiation between pore formation versus membrane disruption by lytic peptides. , 2003, Biochemistry.

[29]  Y. Shai,et al.  Aggregation and organization of pardaxin in phospholipid membranes. A fluorescence energy transfer study. , 1992, The Journal of biological chemistry.

[30]  Y. Shai,et al.  Inhibition of HIV-1 Envelope Glycoprotein-mediated Cell Fusion by a DL-Amino Acid-containing Fusion Peptide , 2004, Journal of Biological Chemistry.

[31]  K. Guthrie,et al.  HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. , 1996, Biochemistry.